H. El-serag and . Hepatocellular-carcinoma, Hepatocellular Carcinoma, New England Journal of Medicine, vol.365, issue.12, pp.1118-1145, 2011.
DOI : 10.1056/NEJMra1001683

J. Bruix, G. Gores, and V. Mazzaferro, Hepatocellular carcinoma: clinical frontiers and perspectives, Gut, vol.19, issue.(Suppl 9), pp.844-55, 2014.
DOI : 10.1136/gutjnl-2013-306627

J. Llovet, A. Villanueva, A. Lachenmayer, and R. Finn, Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nature Reviews Clinical Oncology, vol.26, issue.7, pp.408-432, 2015.
DOI : 10.1158/1078-0432.CCR-13-2107

J. Baselga and S. Swain, Novel anticancer targets: revisiting ERBB2 and discovering ERBB3, Nature Reviews Cancer, vol.25, issue.7, pp.463-75, 2009.
DOI : 10.1038/nrc2656

C. Desbois-mouthon, The HER3/ErbB3 receptor: A promising target in cancer drug therapy, Gastroent??rologie Clinique et Biologique, vol.34, issue.4-5, pp.255-264, 2010.
DOI : 10.1016/j.gcb.2010.03.002

D. Amin, M. Campbell, and M. Moasser, The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics, Seminars in Cell & Developmental Biology, vol.21, issue.9, pp.944-50, 2010.
DOI : 10.1016/j.semcdb.2010.08.007

B. Tanner, D. Hasenclever, K. Stern, W. Schormann, M. Bezler et al., ErbB-3 Predicts Survival in Ovarian Cancer, Journal of Clinical Oncology, vol.24, issue.26, pp.4317-4340, 2006.
DOI : 10.1200/JCO.2005.04.8397

J. Giltnane, C. Moeder, R. Camp, and D. Rimm, Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort, Cancer, vol.12, issue.11, pp.2400-2409, 2009.
DOI : 10.1002/cncr.24277

A. Berghoff, R. Bartsch, M. Preusser, G. Ricken, G. Steger et al., Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients, The Breast, vol.23, issue.5, pp.637-680, 2014.
DOI : 10.1016/j.breast.2014.06.011

M. Reschke, D. Mihic-probst, V. D. Horst, E. Knyazev, P. Wild et al., HER3 Is a Determinant for Poor Prognosis in Melanoma, Clinical Cancer Research, vol.14, issue.16, pp.5188-97, 2008.
DOI : 10.1158/1078-0432.CCR-08-0186

M. Begnami, E. Fukuda, J. Fregnani, S. Nonogaki, A. Montagnini et al., Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome, Journal of Clinical Oncology, vol.29, issue.22, pp.3030-3036, 2011.
DOI : 10.1200/JCO.2010.33.6313

M. Hayashi, M. Inokuchi, Y. Takagi, H. Yamada, K. Kojima et al., High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer, Clinical Cancer Research, vol.14, issue.23, pp.7843-7852, 2008.
DOI : 10.1158/1078-0432.CCR-08-1064

T. Wilson, D. Lee, L. Berry, D. Shames, and J. Settleman, Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers, Cancer Cell, vol.20, issue.2, pp.158-72, 2011.
DOI : 10.1016/j.ccr.2011.07.011

D. Shames, J. Carbon, K. Walter, A. Jubb, C. Kozlowski et al., High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck, PLoS ONE, vol.333, issue.2, p.56765, 2013.
DOI : 10.1371/journal.pone.0056765.s004

A. Memon, B. Sorensen, P. Melgard, L. Fokdal, T. Thykjaer et al., Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients, British Journal of Cancer, vol.5, issue.12, pp.2034-2075, 2004.
DOI : 10.1038/35052073

E. Trocme, D. Mougiakakos, C. Johansson, C. All-eriksson, M. Economou et al., Nuclear HER3 is associated with favorable overall survival in uveal melanoma, International Journal of Cancer, vol.47, issue.5, pp.1120-1127, 2012.
DOI : 10.1002/ijc.26118

B. Pan, R. Wang, Y. Huang, D. Garfield, J. Zhang et al., HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma, OncoTargets and Therapy, vol.8, pp.1185-91, 2015.
DOI : 10.2147/OTT.S78116

Y. Ito, T. Takeda, M. Sakon, M. Tsujimoto, S. Higashiyama et al., Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma, British Journal of Cancer, vol.84, issue.10, pp.1377-83, 2001.
DOI : 10.1054/bjoc.2000.1580

S. Neo, C. Leow, V. Vega, P. Long, A. Islam et al., Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach, Hepatology, vol.29, issue.Suppl, pp.944-53, 2004.
DOI : 10.1002/hep.20105

S. Hsieh, J. He, C. Hsu, W. Chen, R. Bera et al., Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma, Hepatology, vol.68, issue.Suppl 1, pp.504-520, 2011.
DOI : 10.1002/hep.24083

H. Chettouh, L. Fartoux, L. Aoudjehane, D. Wendum, A. Claperon et al., Mitogenic Insulin Receptor-A Is Overexpressed in Human Hepatocellular Carcinoma due to EGFR-Mediated Dysregulation of RNA Splicing Factors, Cancer Research, vol.73, issue.13, pp.3974-86, 2013.
DOI : 10.1158/0008-5472.CAN-12-3824

M. Blivet-van-eggelpoel, H. Chettouh, L. Fartoux, L. Aoudjehane, V. Barbu et al., Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells, Journal of Hepatology, vol.57, issue.1, pp.108-123, 2012.
DOI : 10.1016/j.jhep.2012.02.019

P. Podevin, A. Carpentier, V. Pene, L. Aoudjehane, M. Carriere et al., Production of Infectious Hepatitis C Virus in Primary Cultures of Human Adult Hepatocytes, Gastroenterology, vol.139, issue.4, pp.1355-64, 2010.
DOI : 10.1053/j.gastro.2010.06.058

R. Carver, P. Mathew, and W. Russell, Hepatic Expression of ErbB3 Is Repressed by Insulin in a Pathway Sensitive to PI-3 Kinase Inhibitors, Endocrinology, vol.138, issue.12, pp.5195-201, 1997.
DOI : 10.1210/en.138.12.5195

K. Mujoo, B. Choi, Z. Huang, N. Zhang, and Z. An, Regulation of ERBB3/HER3 signaling in cancer, Oncotarget, vol.5, issue.21, pp.10222-10258, 2014.
DOI : 10.18632/oncotarget.2655

K. Cao, H. Gong, Z. Qiu, Q. Wen, B. Zhang et al., Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells, Tumor Biology, vol.35, issue.8
DOI : 10.1007/s13277-016-4936-y

S. Hsieh, J. He, M. Yu, W. Lee, T. Chen et al., Secreted ERBB3 Isoforms Are Serum Markers for Early Hepatoma in Patients with Chronic Hepatitis and Cirrhosis, Journal of Proteome Research, vol.10, issue.10, pp.4715-4739, 2011.
DOI : 10.1021/pr200519q

S. Stindt, P. Cebula, U. Albrecht, V. Keitel, S. Esch et al., Hepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family, PLOS ONE, vol.287, issue.50, 2016.
DOI : 10.1371/journal.pone.0148711.s001

B. Fuchs, T. Fujii, J. Dorfman, J. Goodwin, A. Zhu et al., Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells, Cancer Research, vol.68, issue.7, pp.2391-2400, 2008.
DOI : 10.1158/0008-5472.CAN-07-2460

H. Zhao, V. Desai, J. Wang, D. Epstein, M. Miglarese et al., Epithelial-Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines, Molecular Cancer Therapeutics, vol.11, issue.2, pp.503-516, 2012.
DOI : 10.1158/1535-7163.MCT-11-0327

K. Meetze, S. Vincent, S. Tyler, E. Mazsa, A. Delpero et al., Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models, Clinical Cancer Research, vol.21, issue.5, pp.1106-1120, 2015.
DOI : 10.1158/1078-0432.CCR-14-2407

A. Ocana, L. Diez-gonzalez, A. Esparis-ogando, J. Montero, E. Amir et al., Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies, Oncotarget

S. Bianchi, D. Palli, M. Falchetti, C. Saieva, G. Masala et al., ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study, Journal of Cellular Physiology, vol.2, issue.3, pp.702-710, 2006.
DOI : 10.1002/jcp.20535

E. Yi, D. Harclerode, M. Gondo, M. Stephenson, R. Brown et al., High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas, Mod Pathol, vol.10, pp.142-150, 1997.

V. Anagnostou, A. Welsh, J. Giltnane, S. Siddiqui, C. Liceaga et al., Analytic Variability in Immunohistochemistry Biomarker Studies, Cancer Epidemiology Biomarkers & Prevention, vol.19, issue.4, pp.982-91, 2010.
DOI : 10.1158/1055-9965.EPI-10-0097

R. Zhande, J. Mitchell, J. Wu, and X. Sun, Molecular Mechanism of Insulin-Induced Degradation of Insulin Receptor Substrate 1, Molecular and Cellular Biology, vol.22, issue.4, pp.1016-1042, 2002.
DOI : 10.1128/MCB.22.4.1016-1026.2002

H. Matsuzaki, H. Daitoku, M. Hatta, K. Tanaka, and A. Fukamizu, Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation, Proceedings of the National Academy of Sciences, vol.100, issue.20, pp.11285-90, 2003.
DOI : 10.1073/pnas.1934283100

H. Chettouh, M. Lequoy, L. Fartoux, and C. Vigouroux, Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma, Liver International, vol.21, issue.10, pp.2203-2220, 2015.
DOI : 10.1111/liv.12903